{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:06:12Z","timestamp":1784315172565,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients\u2019 outcomes and experiences can be affected by rheumatologist knowledge and awareness of systemic sclerosis (SSc). Our survey, directed at UK-based rheumatologists, aimed to expand our understanding of the above points along with their ability to keep up to date with guidelines defining best practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Rheumatologists were invited to participate in an online survey, with the results analysed and presented descriptively and graphically by SRUK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 150 UK rheumatologists surveyed, 2% reported that they had not heard of SSC and 18.7% reported having a limited understanding of the condition. A total of 44% of respondents reported that they were fully versed in the signs and symptoms of SSc. The majority of those surveyed shared the broad view that all aspects of SSc, including services (63.4%), specialist positions (64.7%), research (73.1%) and training and education (70%), are either completely or somewhat underfunded. Most respondents (87.4%) reported that their workload allowed them to \u2018somewhat\u2019 (48.74%) or \u2018completely\u2019 (38.66%) keep up to date with official guidelines. Scleroderma and Raynaud\u2019s UK (SRUK) (47.9%), followed by NICE (43.7%), were the most highly used sources of information utilized among those surveyed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our survey reveals a serious gap in the awareness and the signs and symptoms of SSc among some UK rheumatologists, in addition to a perception that services, training and education in this area are underfunded. Our findings indicate that there is a role for the provision of further education and training as part of continued professional development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae152","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:17:26Z","timestamp":1734675446000},"source":"Crossref","is-referenced-by-count":3,"title":["A Scleroderma and Raynaud\u2019s UK (SRUK) national survey to explore rheumatologists\u2019 awareness, approaches to diagnosis and management and training needs within systemic sclerosis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-2772","authenticated-orcid":false,"given":"Emma","family":"Blamont","sequence":"first","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Farrington","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Glover-Southworth","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Cornwell","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gibson","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sloan","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4909","authenticated-orcid":false,"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre , Manchester,","place":["UK"]},{"name":"Department of Rheumatology, Northern Care Alliance NHS Foundation Trust, Salford Care Organisation , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025030418594921900_rkae152-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2025030418594921900_rkae152-B2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s10067-018-4182-3","article-title":"The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink","volume":"37","author":"Royle","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025030418594921900_rkae152-B3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.12968\/hmed.2019.80.9.530","article-title":"Systemic sclerosis","volume":"80","author":"Hughes","year":"2019","journal-title":"Br J Hosp Med"},{"key":"2025030418594921900_rkae152-B4","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/rheumatology\/keaa680","article-title":"Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink","volume":"60","author":"Pauling","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025030418594921900_rkae152-B5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"2025030418594921900_rkae152-B6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025030418594921900_rkae152-B7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030418594921900_rkae152-B8","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025030418594921900_rkae152-B9","first-page":"rkad022","article-title":"Management of systemic sclerosis: British Society for Rheumatology guideline scope","volume-title":"Rheumatol Adv Pract","author":"Denton","year":"2023"},{"key":"2025030418594921900_rkae152-B10","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030418594921900_rkae152-B11","author":"Scleroderma and Raynaud\u2019s UK"},{"key":"2025030418594921900_rkae152-B12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/annrheumdis-2018-214161","article-title":"Patient organisation-led initiatives can play an important role in raising awareness about Raynaud\u2019s phenomenon and encourage earlier healthcare utilisation for high-risk groups","volume":"78","author":"Hughes","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030418594921900_rkae152-B13","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s10067-020-05023-5","article-title":"A systematic review of internet-based information for individuals with Raynaud\u2019s phenomenon and patients with systemic sclerosis","volume":"39","author":"Devgire","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025030418594921900_rkae152-B14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025030418594921900_rkae152-B15","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2025030418594921900_rkae152-B16","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae152\/61242156\/rkae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/1\/rkae152\/61242156\/rkae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/1\/rkae152\/61242156\/rkae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:59:22Z","timestamp":1741121962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae152\/7929225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae152","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,18]]},"article-number":"rkae152"}}